Stockscreener 앱 받기
4.10
11.26%
-0.52
시간 외 거래:
4.18
0.08
+1.95%
전일 마감가:
$4.62
열려 있는:
$4.5
하루 거래량:
36,505
Relative Volume:
0.12
시가총액:
$23.14M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-28.45%
1개월 성능:
-15.81%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.09
$4.57
1주일 범위
$4.09
$5.60
52주 변동 폭
$4.09
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
명칭
Vyome Holdings Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
HIND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
4.10 | 26.08M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vyome Holdings Inc 주식(HIND)의 최신 뉴스
Vyome inches towards US FDA approval to enter $1B worth malignant fungating wound market - BioSpectrum India
Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints - MSN
Check Out Vyome Holdings Inc (HIND)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval - BioSpace
Vyome stock soars after malodor treatment shows positive results - Investing.com
Vyome stock soars after malodor treatment shows positive results By Investing.com - Investing.com UK
Vyome reports positive final Phase 2 results for VT-1953, plans to advance into pivotal study for FDA approval - marketscreener.com
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
Vyome Holdings (HIND) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
JOLLY MOHANJIT Insider Trades - Nasdaq
Vyome Holdings, Inc. (HIND) Recent Insider Transactions - Yahoo! Finance Canada
Vyome Holdings, Inc. (HIND) recent insider transactions - Yahoo Finance UK
Vyome Holdings, Inc. (HIND) Profit Margin (Quarterly) - Zacks Investment Research
Vyome Holdings files prospectus related to resale of 610,185 shares of common stock by selling stockholders - marketscreener.com
Vyome Holdings Files Prospectus Related To Resale Of 610,185 Shares Of Common Stock By Selling Stockholders - TradingView
Vyome Holdings Inc. Reports Post-Merger Financials - MSN
Vyome taps Dr. Bardia as senior medical advisor for wound treatment - Investing.com Nigeria
Vyome Appoints Dr. Aditya Bardia as Senior Medical Advisor - citybiz
Vyome taps Dr. Bardia as senior medical advisor for wound treatment By Investing.com - Investing.com South Africa
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program - Yahoo Finance
Earnings call transcript: Vyome Holdings Q3 2025 sees strategic advancements - Investing.com Nigeria
Vyome Therapeutics2025 Latest Shareholding - Tracxn
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing - Bluefield Daily Telegraph
Vyome Holdings Inc. (HIND) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vyome Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
HIND Forecast — Price Target — Prediction for 2026 - TradingView
Critical Contrast: Vyome (NASDAQ:HIND) vs. TranS1 (OTCMKTS:BAXSQ) - Defense World
Working capital per share of Vyome Holdings, Inc. – MUN:H1O - TradingView
ReShape Lifesciences (OTCMKTS:RSLSD) vs. Vyome (NASDAQ:HIND) Critical Analysis - Defense World
Vyome Holdings Announces Results of Annual Shareholder Meeting - The Joplin Globe
Contrasting ReShape Lifesciences (OTCMKTS:RSLSD) & Vyome (NASDAQ:HIND) - Defense World
Comparing Anzu Special Acquisition Corp I (NASDAQ:ANZUW) & Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Elects Directors at Annual Meeting - MSN
Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - Markets Financial Content
Head-To-Head Contrast: Vyome (NASDAQ:HIND) & TranS1 (OTCMKTS:BAXSQ) - Defense World
ReShape Lifesciences : trade; to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate UpdateForm 8-K/A - MarketScreener
Tincoff John M. Iii Net Worth (2025) - GuruFocus
ReShape Lifesciences (OTCMKTS:RSLSD) versus Vyome (NASDAQ:HIND) Financial Survey - Defense World
Will Vyome's Topical Gel Be The First FDA-Approved Treatment For Cancer Wounds? - RTTNews
Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Acquires AI Startup Oculo, Inc. - TipRanks
HIND Analyst Forecasts - Quiver Quantitative
Vyome Holdings acquires Oculo Health - Medical Buyer
Vyome Holdings Acquires MIT Spinout Oculo Health, Launches AI Psychiatrist Business Unit - Sahyadri Startups
Vyome Holdings Acquires MIT AI Spinout Oculo Health - citybiz
Vyome Holdings Inc (HIND) 재무 분석
Vyome Holdings Inc (HIND)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.36%
1.12%
자본화:
|
볼륨(24시간):